SBIO: Big Pharma Needs What This Fund Owns
CG Oncology Inc CGON
$70.52
▲ +1.31%
(+$0.91)
⬆️ Above Yest. High
Open
$69.56
Prev Close
$69.61
Day Range
$68.26 – $70.68
52W Range
$35.80 – $80.97
Market Cap
$6.25B
Beta
0.24
EPS (TTM)
$-2.70
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-01-25 |
| Shares Out. | 88,200,000 |
| Website | cgoncology.com/ ↗ |
| Phone | 13025310855 |
| Employees | 142 |
| Revenue | $1.2M |
| Gross Profit | -$2.8M |
| Net Income | -$79.1M |
| Free Cash Flow | -$179.3M |
| Total Assets | $1.09B |
| Total Liabilities | $56.5M |
| Equity | $1.03B |
About CG Oncology Inc
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology Inc is a publicly traded company under the ticker symbol CGON on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-09-01)